Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07385313 · ClinicalTrials.gov registry record · Phase 4
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
A Phase 4 study, sponsored by Aroa Biosurgery Limited.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07385313: Recruiting Phase 4 study, sponsored by Aroa Biosurgery Limited.
NCT07385313 is a Phase 4 study that is actively recruiting participants, run by Aroa Biosurgery Limited. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07385313, a Phase 4 study, is actively recruiting participants, sponsored by Aroa Biosurgery Limited.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Demonstrate faster tissue coverage of exposed structures using OFM in combination with negative pressure wound therapy (NPWT), versus NPWT alone
Primary Outcome
Time (days) to complete tissue coverage of the exposed structure
Interventions
- DEVICE Myriad™ applied in conjunction with NPWT
- DEVICE NPWT Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What NCT07385313 shows while recruiting
NCT07385313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Myriad™ applied in conjunction with NPWT is the first listed.
NCT07385313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07385313 about?
NCT07385313 is a clinical study titled "Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures". Demonstrate faster tissue coverage of exposed structures using OFM in combination with negative pressure wound therapy (NPWT), versus NPWT alone
What is the current status of trial NCT07385313?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-03-31. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07385313?
The interventions under investigation include: Myriad™ applied in conjunction with NPWT (DEVICE), NPWT Alone (DEVICE).
Who is sponsoring clinical trial NCT07385313?
This trial is sponsored by Aroa Biosurgery Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07385313's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI